Page 45 - Haematologica April 2020

RUNX1 variant curation
52. Cavalcante de Andrade Silva M, Krepischi ACV, Kulikowski LD, et al. Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia. Cancer Genet. 2018;222-223:32-37.
53. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
54. Luddy RE, Champion LA, Schwartz AD. A fatal myeloproliferative syndrome in a fam- ily with thrombocytopenia and platelet dys- function. Cancer. 1978;41(5):1959-1963.
55. Dowton SB, Beardsley D, Jamison D, Blattner S, Li FP. Studies of a familial platelet disorder. Blood. 1985;65(3):557-563.
56. Liew E, Owen C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011;96(10):1536-1542.
57. Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a lim- ited region of a single gene, AML1. Proc Natl Acad Sci U S A. 1991;88(23):10431-10434.
58. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similari- ty to Drosophila segmentation gene, runt. Blood. 1992;80(7):1825-1831.
59. Feurstein S, Drazer MW, Godley LA. Genetic predisposition to leukemia and other hematologic malignancies. Semin Oncol. 2016;43(5):598-608.
60. Churpek JE, LA G. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128 (14):1800-1813.
61. Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoi- etic stem cells in acute leukaemia. Nature. 2014;506(7488):328-333.
62. Arends CM, Galan-Sousa J, Hoyer K, et al. Hematopoietic lineage distribution and evo- lutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32(9):1908-1919.
63. Thol F, Klesse S, Kohler L, et al. Acute myeloid leukemia derived from lympho- myeloid clonal hematopoiesis. Leukemia. 2017;31(6):1286-1295.
tent stem cells. Circulation. 2018;138(23):
2666-2681.
73. Sander JD, Joung JK. CRISPR-Cas systems
for editing, regulating and targeting
genomes. Nat Biotechnol. 2014;32(4):347- Mutation detection in thousand of acute 355.
64. Petti AA, Williams SR, Miller CA, et al.
myeloid leukemia cells using single cell RNA-sequencing. bioRxiv. 2018 October 17. [Epub ahead of Print]
65. Velten L, Story BA, Hernancez-Malmierca P, et al. MutaSeq reveals the transcriptomic consequences of clonal evolution in acute myeloid leukemia. bioRxiv. 2018 December 21 [Epub ahead of Print]
66. Wehr C, Grotius K, Casadei S, et al. A novel disease-causing synonymous exonic muta- tion in GATA2 affecting RNA splicing. Blood. 2018;132(11):1211-1215.
67. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by muta- tions in a conserved intronic element leads to MonoMAC syndrome. Blood. 2013;121(19):3830-38371.
68. Pippucci T, Savoia A, Perrotta S, et al. Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet. 2011;88(1):115-120.
69. Noris P, Perrotta S, Seri M, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analy- sis of 78 patients from 21 families. Blood. 2011;117(24):6673-6680.
70. Azzariti DR, Riggs ER, Niehaus A, et al. Points to consider for sharing variant-level information from clinical genetic testing with ClinVar. Cold Spring Harb Mol Case Stud. 2018;4(1).
71. Riggs ER, Azzariti DR, Niehaus A, et al. Development of a consent resource for genomic data sharing in the clinical setting. Genet Med. 2019;21(1):81-88.
72. Ma N, Zhang JZ, Itzhaki I, et al. Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripo-
74. Tsai SQ, Joung JK. Defining and improving the genome-wide specificities of CRISPR- Cas9 nucleases. Nat Rev Genet. 2016;17(5):300-312.
75. Zhang L, Li Z, Yan J, et al. Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit. J Biol Chem. 2003;278(35):33097-33104.
76. Li Z, Yan J, Matheny CJ, et al. Energetic con- tribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem. 2003;278(35):33088-33096.
77. Findlay GM, Boyle EA, Hause RJ, Klein JC, Shendure J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature. 2014;513(7516):120-123.
78. Findlay GM, Daza RM, Martin B, et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature. 2018;562(7726):217-222.
79. Matreyek KA, Starita LM, Stephany JJ, et al. Multiplex assessment of protein variant abundance by massively parallel sequenc- ing. Nat Genet. 2018;50(6):874-882.
80. Mester JL, Ghosh R, Pesaran T, et al. Gene- specific criteria for PTEN variant curation: recommendations from the ClinGen PTEN Expert Panel. Hum Mutat. 2018;39(11):1581- 1592.
81. Garrett LT, Hickman N, Jacobson A, et al. Family studies for classification of variants of uncertain classification: current laborato- ry clinical practice and a new web-based educational tool. J Genet Couns. 2016;25(6): 1146-1156.
82. Bravo J, Li Z, Speck NA, Warren AJ. The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp. Nat Struct Biol. 2001;8 (4):371-378.
haematologica | 2020; 105(4)
887